Scandion Oncology

Overcoming cancer drug resistance

Navbar
  • About us
    • Executive Management
    • Board of Directors
    • Clinical Advisory Board
  • Research & Development
    • Pipeline
    • Clinical Development
    • Science
      • Cancer drug resistance
      • Technology Platform
      • SCO-101
  • News & Press
    • Press releases
    • Media
      • Image library
      • Video library
  • Investors
    • Share information
    • Financial calendar
    • Financial Reports
      • Annual reports
      • Interim reports
    • Presentations
    • Business development
    • Analyst Coverage
    • Prospectuses
      • Subscription TO2 warrants
      • Rights Issue 2024
      • Rights Issue 2022
      • Rights Issue 2020
      • Rights Issue 2019
      • Subscription Warrant (SCOL TO 1)
      • IPO 2018
    • Corporate governance
    • Events
      • General meetings
  • Contact
    • Career
Skip to content
Regulatory
29 August 2024

Press releases

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
29 August 2024 Scandion Oncology – Interim Report Q2 2024 Download Presentation Webcast Workbook
23 August 2023 Scandion Oncology – Interim Report Q2 2023 Download Presentation Webcast Workbook
25 August 2022 Scandion Oncology – Interim Report Q2 2022 Download Presentation Webcast Workbook
19 August 2021 Interim Report 1 April – 30 June 2021 Download Presentation Webcast Workbook
20 August 2020 Half-Year Report 1 January 2020 – 30 June 2020 Download Presentation Webcast Workbook
22 August 2019 Interim Report 1 January – 30 June 2019 Download Presentation Webcast Workbook
  1. Frontpage

About us

  • About us
  • Executive Management
  • Board of Directors
  • Clinical Advisory Board

Research & Development

  • Research & Development
  • Pipeline
  • Clinical Development
  • Science

News & Press

  • Press releases
  • Other news
  • Media
    • Image library items
    • Video library items

Investors

  • Investors
  • Share information
  • Financial Reports
  • Presentations
  • Analyst Coverage
  • Prospectuses
  • Corporate governance
  • Events

Contact us

Scandion Oncology A/S
Symbion
Fruebjergvej 3
2100 Copenhagen
Denmark

Phone: +45 38 10 20 17
info@scandiononcology.com

Media and Investor relations:
Email: ir@scandiononcology.com
Phone: +45 29 60 35 32

Follow us

Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Disclaimer: Market data could be delayed. Delivered by Cision.